Login
$IONS Congressional Trades
$43.96 +$0.54 (1.24%) Close

Congressional Trades in Ionis Pharmaceuticals, Inc.

What members of the House and Senate report owning and trading in IONS, as filed with the House Clerk and the Senate. Every row links to the filing it came from.

Trades, last 12 months
0
by 0 members
Buys / sells
0 / 0
0 bought, 0 sold
Members reporting IONS
0
in their latest annual report
Reported after the trade
–
median, last 12 months

Members who report holding IONS

As filed in each member's latest annual report, in the ranges the form uses.

No sitting member's latest annual report lists IONS.

Traded Member Trade Amount Investor Reported Source
Dec 6, 2022 Ro Khanna House · D · CA-17 Buy $1K – $15K Spouse Jan 6, 2023 31 days later Scan
Sep 28, 2021 Ro Khanna House · D · CA-17 Buy $1K – $15K Child Oct 14, 2021 16 days later Scan
May 8, 2019 Donna E. Shalala House · D · FL-27 Buy · Stock $1K – $15K Self Apr 27, 2020 355 days later Filing
Apr 3, 2018 Ro Khanna House · D · CA-17 Buy $1K – $15K Spouse May 10, 2018 37 days later Scan
Nov 2, 2016 Thomas MacArthur House · R · NJ-3 Buy $15K – $50K Joint Dec 2, 2016 30 days later Filing

Listed in annual reports

Transactions an annual report lists for the year it covers, apart from trade reports. Not counted in the trades above.

Traded Member Trade Amount Investor Report
Feb 2, 2016 Thomas MacArthur Partial sale $15K – $50K Joint 2016 Annual Report filed May 15, 2017
Dec 22, 2015 Thomas MacArthur Exchange $50K – $100K Joint 2015 Annual Report filed Jul 14, 2016

Members report each trade in a range, not an exact amount, and have up to 45 days to report it. Some filings are scans; where we could not read a scanned field with confidence it is left blank rather than guessed, and the filing link shows the original.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support